These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28575151)

  • 1. Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease.
    Parbo P; Ismail R; Hansen KV; Amidi A; Mårup FH; Gottrup H; Brændgaard H; Eriksson BO; Eskildsen SF; Lund TE; Tietze A; Edison P; Pavese N; Stokholm MG; Borghammer P; Hinz R; Aanerud J; Brooks DJ
    Brain; 2017 Jul; 140(7):2002-2011. PubMed ID: 28575151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An early and late peak in microglial activation in Alzheimer's disease trajectory.
    Fan Z; Brooks DJ; Okello A; Edison P
    Brain; 2017 Mar; 140(3):792-803. PubMed ID: 28122877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.
    Fan Z; Okello AA; Brooks DJ; Edison P
    Brain; 2015 Dec; 138(Pt 12):3685-98. PubMed ID: 26510952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.
    Wiley CA; Lopresti BJ; Venneti S; Price J; Klunk WE; DeKosky ST; Mathis CA
    Arch Neurol; 2009 Jan; 66(1):60-7. PubMed ID: 19139300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
    Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
    Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.
    Edison P; Archer HA; Gerhard A; Hinz R; Pavese N; Turkheimer FE; Hammers A; Tai YF; Fox N; Kennedy A; Rossor M; Brooks DJ
    Neurobiol Dis; 2008 Dec; 32(3):412-9. PubMed ID: 18786637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
    Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
    Kreisl WC; Lyoo CH; McGwier M; Snow J; Jenko KJ; Kimura N; Corona W; Morse CL; Zoghbi SS; Pike VW; McMahon FJ; Turner RS; Innis RB;
    Brain; 2013 Jul; 136(Pt 7):2228-38. PubMed ID: 23775979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
    Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study.
    Okello A; Edison P; Archer HA; Turkheimer FE; Kennedy J; Bullock R; Walker Z; Kennedy A; Fox N; Rossor M; Brooks DJ
    Neurology; 2009 Jan; 72(1):56-62. PubMed ID: 19122031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.
    Jack CR; Lowe VJ; Senjem ML; Weigand SD; Kemp BJ; Shiung MM; Knopman DS; Boeve BF; Klunk WE; Mathis CA; Petersen RC
    Brain; 2008 Mar; 131(Pt 3):665-80. PubMed ID: 18263627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer's disease.
    Parbo P; Madsen LS; Ismail R; Zetterberg H; Blennow K; Eskildsen SF; Vorup-Jensen T; Brooks DJ
    Alzheimers Res Ther; 2020 Jan; 12(1):3. PubMed ID: 31898549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.
    Fan Z; Aman Y; Ahmed I; Chetelat G; Landeau B; Ray Chaudhuri K; Brooks DJ; Edison P
    Alzheimers Dement; 2015 Jun; 11(6):608-21.e7. PubMed ID: 25239737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
    Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early microglial activation and peripheral inflammation in dementia with Lewy bodies.
    Surendranathan A; Su L; Mak E; Passamonti L; Hong YT; Arnold R; Vázquez Rodríguez P; Bevan-Jones WR; Brain SAE; Fryer TD; Aigbirhio FI; Rowe JB; O'Brien JT
    Brain; 2018 Dec; 141(12):3415-3427. PubMed ID: 30403785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study.
    Parbo P; Ismail R; Sommerauer M; Stokholm MG; Hansen AK; Hansen KV; Amidi A; Schaldemose JL; Gottrup H; Brændgaard H; Eskildsen SF; Borghammer P; Hinz R; Aanerud J; Brooks DJ
    Neurobiol Dis; 2018 Sep; 117():211-216. PubMed ID: 29902557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
    Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
    Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.